Research uncovers how to target ‘sleeping’ breast cancer cells and pr
Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat.
Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat.
Supported by an independent educational grant from Servier. Join us for an interactive a nd engaging symposium that takes a deep dive into the latest…
Tune in to this week’s VJHemOnc podcast to learn more about current & emerging treatment options for acute & chronic GvHD, as well as the…
Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
Learn more about what Crucial Catch is and how the NFL and ACS have teamed up to fight cancer. Find links to buy Crucial Catch…
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.